JP2016516800A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016516800A5 JP2016516800A5 JP2016508192A JP2016508192A JP2016516800A5 JP 2016516800 A5 JP2016516800 A5 JP 2016516800A5 JP 2016508192 A JP2016508192 A JP 2016508192A JP 2016508192 A JP2016508192 A JP 2016508192A JP 2016516800 A5 JP2016516800 A5 JP 2016516800A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- egfr antibody
- fucose
- cancer
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13002106 | 2013-04-22 | ||
| EP13002108.2 | 2013-04-22 | ||
| EP13002106.6 | 2013-04-22 | ||
| EP13002108 | 2013-04-22 | ||
| PCT/EP2014/058118 WO2014173886A1 (en) | 2013-04-22 | 2014-04-22 | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016516800A JP2016516800A (ja) | 2016-06-09 |
| JP2016516800A5 true JP2016516800A5 (https=) | 2017-05-25 |
Family
ID=50729450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016508192A Withdrawn JP2016516800A (ja) | 2013-04-22 | 2014-04-22 | フコシル化が少ない抗ｅｇｆｒ抗体による抗がん処置 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20160068609A1 (https=) |
| EP (1) | EP2989126A1 (https=) |
| JP (1) | JP2016516800A (https=) |
| KR (1) | KR20150144804A (https=) |
| CN (1) | CN105229030A (https=) |
| AU (1) | AU2014257650A1 (https=) |
| BR (1) | BR112015025955A2 (https=) |
| CA (1) | CA2908819A1 (https=) |
| EA (1) | EA201591977A1 (https=) |
| MX (1) | MX2015014773A (https=) |
| SG (1) | SG11201507743XA (https=) |
| WO (1) | WO2014173886A1 (https=) |
| ZA (1) | ZA201507246B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| CN105820248A (zh) * | 2015-01-07 | 2016-08-03 | 上海张江生物技术有限公司 | 一种新型抗egfr单克隆抗体的制备方法及应用 |
| CN105399830B (zh) * | 2015-09-08 | 2019-11-19 | 北京天广实生物技术股份有限公司 | 抗egfr人源化单克隆抗体、其制备方法及用途 |
| US20170247458A1 (en) * | 2016-01-10 | 2017-08-31 | Sorrento Therapeutics, Inc. | Safety for Treating Cancers with a Glycosylated Chimeric Antibody to EGFR |
| SI3449939T1 (sl) | 2016-04-27 | 2022-06-30 | Green Cross Corporation | Farmacevtski sestavek za zaviranje metastaz pri raku, ki kot učinkovino obsega protitelo, ki se specifično veže na receptor za epidermalni rastni faktor |
| US11649291B2 (en) | 2016-05-24 | 2023-05-16 | Insmed Incorporated | Antibodies and methods of making same |
| WO2018013673A1 (en) * | 2016-07-13 | 2018-01-18 | Reform Biologics, Llc | Stabilizing excipients for therapeutic protein formulations |
| KR101884614B1 (ko) | 2016-10-11 | 2018-08-02 | 신일제약주식회사 | Fab 단편 및 이의 용도 |
| CN111315776A (zh) * | 2017-03-29 | 2020-06-19 | 葛莱高托普有限公司 | Pd-l1和ta-muc1抗体 |
| CN118267470A (zh) * | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| KR20200031571A (ko) * | 2017-05-29 | 2020-03-24 | 가마맵스 파마 | 암 연관 면역억제의 억제제 |
| US20210269530A1 (en) * | 2018-05-14 | 2021-09-02 | Harpoon Therapeutics, Inc. | Conditionally activated binding protein comprising a sterically occluded target binding domain |
| WO2020061482A1 (en) | 2018-09-21 | 2020-03-26 | Harpoon Therapeutics, Inc. | Egfr binding proteins and methods of use |
| JP7493237B2 (ja) * | 2018-11-14 | 2024-05-31 | 学校法人金沢医科大学 | びまん性胃がんを治療するための医薬組成物 |
| CN112300278A (zh) * | 2019-07-25 | 2021-02-02 | 上海交通大学 | 抗人egfr嵌合抗体及其制备方法和用途 |
| MX2022013182A (es) * | 2020-04-24 | 2023-01-16 | Merus Nv | Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr. |
| CN115960214A (zh) * | 2021-10-12 | 2023-04-14 | 中国科学院分子细胞科学卓越创新中心 | 中和呼吸道合胞病毒的全人抗体的设计及应用 |
| EP4476263A4 (en) * | 2022-02-09 | 2026-01-28 | Dragonfly Therapeutics Inc | PHARMACEUTICAL FORMULATIONS AND THERAPEUTIC USES OF MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO EGFR, NKG2D AND CD16 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| EP1176195B1 (en) | 1999-04-09 | 2013-05-22 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| EP2322644A1 (en) | 2000-06-28 | 2011-05-18 | GlycoFi, Inc. | Methods for producing modified glycoproteins |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| CA2481920A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Antibody composition-containing medicament |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| AU2006211037B2 (en) * | 2005-02-07 | 2012-05-24 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
| SI2073842T1 (sl) | 2006-09-10 | 2015-05-29 | Glycotope Gmbh | Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles |
| US20110200595A1 (en) * | 2010-02-18 | 2011-08-18 | Roche Glycart | TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR |
| WO2012020065A1 (en) * | 2010-08-10 | 2012-02-16 | Glycotope Gmbh | Fab-glycosylated antibodies |
| EP2603527A1 (en) * | 2010-08-10 | 2013-06-19 | Glycotope GmbH | Humanized egfr antibodies |
-
2014
- 2014-04-22 US US14/784,470 patent/US20160068609A1/en not_active Abandoned
- 2014-04-22 CN CN201480021328.XA patent/CN105229030A/zh active Pending
- 2014-04-22 BR BR112015025955A patent/BR112015025955A2/pt not_active IP Right Cessation
- 2014-04-22 WO PCT/EP2014/058118 patent/WO2014173886A1/en not_active Ceased
- 2014-04-22 CA CA2908819A patent/CA2908819A1/en not_active Abandoned
- 2014-04-22 AU AU2014257650A patent/AU2014257650A1/en not_active Abandoned
- 2014-04-22 SG SG11201507743XA patent/SG11201507743XA/en unknown
- 2014-04-22 MX MX2015014773A patent/MX2015014773A/es unknown
- 2014-04-22 JP JP2016508192A patent/JP2016516800A/ja not_active Withdrawn
- 2014-04-22 EP EP14724007.1A patent/EP2989126A1/en not_active Withdrawn
- 2014-04-22 KR KR1020157033309A patent/KR20150144804A/ko not_active Withdrawn
- 2014-04-22 EA EA201591977A patent/EA201591977A1/ru unknown
-
2015
- 2015-09-30 ZA ZA2015/07246A patent/ZA201507246B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016516800A5 (https=) | ||
| AU2021202413B2 (en) | Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors | |
| Agustoni et al. | EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis | |
| JP7122357B2 (ja) | がんの治療のための方法、組成物、及びキット | |
| Henricks et al. | The use of combinations of monoclonal antibodies in clinical oncology | |
| JP2016516800A (ja) | フコシル化が少ない抗ｅｇｆｒ抗体による抗がん処置 | |
| JP7797875B2 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| TW201545759A (zh) | 用於治療非小細胞肺癌之抗ｂ７－ｈ１及抗ｃｔｌａ－４抗體 | |
| Baldo | Monoclonal antibodies approved for cancer therapy | |
| Jarboe et al. | Therapeutic human monoclonal antibodies against cancer | |
| JP2020522562A5 (https=) | ||
| JP2025060639A (ja) | Ｐｄ－１／ｐｄ－ｌ１シグナル伝達阻害剤に不応答性のがんの処置方法および医薬 | |
| EP3463453A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| JPWO2022270524A5 (https=) | ||
| Ameri et al. | Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer | |
| CN104394887A (zh) | 采用具有低岩藻糖化的抗her2抗体的新治疗性疗法 | |
| CN110177807B (zh) | 使用抗MUC1抗体和ErbB抑制剂的抗癌治疗 | |
| JP2012025694A (ja) | 癌治療剤 | |
| Wan et al. | Progress of immune checkpoint inhibitors in gastric cancer | |
| Ramanathan | Alternative dosing schedules for cetuximab: a role for biweekly administration? | |
| WO2022232503A1 (en) | Therapeutic and diagnostic methods and compositions for cancer | |
| CN116745322A (zh) | 使用抗岩藻糖基-gm1抗体的组合疗法 | |
| Rahman et al. | Monoclonal antibody: a cell specific immunotherapy to treat cancer | |
| WO2021143671A1 (zh) | 抗pd-1抗体和喹唑啉衍生物的药物组合以及其用途、使用其的方法 | |
| KR20200105825A (ko) | 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도 |